The short answer
In ATTAIN-MAINTAIN, people switched to daily orforglipron kept more of their previous weight loss than those switched to placebo.
Who took part?
Researchers randomized 376 former SURMOUNT-5 participants: 205 previously taking tirzepatide and 171 previously taking semaglutide.
Results
Among participants whose weight had reached a plateau, the estimated share of previous weight loss retained was:
Percent of previous weight loss, not body weight
Original chart based on the study. Values are reported group results.
| Group or measure | Result |
|---|---|
| Prior tirzepatide: orforglipron | 74.7% |
| Prior tirzepatide: placebo | 49.2% |
| Prior semaglutide: orforglipron | 79.3% |
| Prior semaglutide: placebo | 37.6% |
These are percentages of weight already lost, not percentages of starting body weight or the proportion of people who succeeded. They are model-based estimates at 52 weeks.
What does it mean?
The findings support studying maintenance options beyond injections. They do not establish that switching works as well as staying on an injectable medicine.
Digestive side effects were the most common, generally mild or moderate. Follow-up lasted one year, and participants had already completed an earlier treatment trial.
Sources
Aronne and colleagues, Nature Medicine, 2026. Funded by Eli Lilly. Read the study.